Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Boosted by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 9.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 17,495 shares of the company’s stock after buying an additional 1,545 shares during the quarter. New York State Common Retirement Fund’s holdings in Viridian Therapeutics were worth $378,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Knights of Columbus Asset Advisors LLC boosted its position in shares of Viridian Therapeutics by 2.9% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 29,553 shares of the company’s stock worth $453,000 after buying an additional 823 shares during the period. Silverarc Capital Management LLC lifted its position in shares of Viridian Therapeutics by 5.4% during the 3rd quarter. Silverarc Capital Management LLC now owns 47,438 shares of the company’s stock worth $728,000 after purchasing an additional 2,438 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Viridian Therapeutics by 17.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,227 shares of the company’s stock worth $448,000 after buying an additional 4,412 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Viridian Therapeutics by 122.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock valued at $182,000 after purchasing an additional 4,610 shares during the period. Finally, Swiss National Bank grew its position in Viridian Therapeutics by 9.4% in the 3rd quarter. Swiss National Bank now owns 66,400 shares of the company’s stock worth $1,019,000 after purchasing an additional 5,700 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on VRDN. HC Wainwright cut their price objective on shares of Viridian Therapeutics from $37.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a report on Thursday, May 9th. B. Riley lowered Viridian Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $25.00 to $20.00 in a report on Thursday, May 9th. Oppenheimer cut their target price on Viridian Therapeutics from $36.00 to $31.00 and set an “outperform” rating for the company in a research note on Thursday, May 9th. Finally, LADENBURG THALM/SH SH downgraded shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.60.

Viridian Therapeutics Stock Performance

Shares of NASDAQ:VRDN opened at $14.27 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. The business’s fifty day moving average price is $15.99 and its two-hundred day moving average price is $17.73. Viridian Therapeutics, Inc. has a fifty-two week low of $10.93 and a fifty-two week high of $28.35. The stock has a market capitalization of $910.71 million, a price-to-earnings ratio of -3.17 and a beta of 1.14.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Wednesday, May 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.28. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the prior year, the firm earned ($1.61) EPS. The firm’s quarterly revenue was down 26.5% compared to the same quarter last year. As a group, analysts predict that Viridian Therapeutics, Inc. will post -3.61 EPS for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.